Half Year 2022 Financial Results and Business Update September 15, 2022 PARIS: IPH.PA NASDAQ: IPHA © 2021 Innate Pharma. All rights reserved. Disclaimer on Forward-Looking Information and Risk Factors This document has been prepared by Innate Pharma S.A. (the "Company") solely for the purposes of a presentation to investors concerning the Company. This document is not to be reproduced by any person, nor to be distributed. This document contains forward-looking statements. The use of certain words, including ...

INNATE PHARMA SA HALF-YEAR FINANCIAL REPORT JUNE 30, 2022 INNATE PHARMA S.A. French société anonyme governed by an Executive Board and a Supervisory Boardé with a share capital of 3,995,355.70 euros composed of 79,893,019 ordinary shares, and 14,095 preferred shares with a nominal value of 0.05 euros each Registered office: 117, Avenue de Luminy, F-13009 Marseille, France Registered with the Company and Trade Register of Marseille under number 424 365 336 The following interim condensed consolidated financi ...

Innate Pharma SA (NASDAQ:IPHA) Q1 2022 Earnings Conference Call May 10, 2022 8:00 AM ET Company Participants Henry Wheeler - VP and Head of IR Mondher Mahjoubi - Chairman of Executive Board and CEO Joyson Karakunnel - Executive VP and Chief Medical Officer Yannis Morel - Executive VP of Product Portfolio Strategy and Business Development and Member of Executive Board Conference Call Participants Daina Graybosch - SVB Leerink Olga Smolentseva - Bryan Garnier Jingming Chen - Evercore Arthur He - H.C. Wainwrig ...

Company Overview March 2022 PARIS: IPH.PA NASDAQ: IPHA © 2020 Innate Pharma. All rights reserved. Disclaimer on Forward-Looking Information and Risk Factors This document has been prepared by Innate Pharma S.A. (the "Company") solely for the purposes of a presentation to investors concerning the Company. This document is not to be reproduced by any person, nor to be distributed. This document contains forward-looking statements. The use of certain words, including "believe," "potential," "expect" and "will" ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ OR ☐ SHELL COMPANY REPORT PURSUANT TO SE ...

Financial Data and Key Metrics Changes - Cash and cash equivalents amounted to €159.7 million as of December 31, 2021, including a state-guaranteed loan of €28.7 million received in December 2021 [31] - Revenue and other income totaled €24.7 million, primarily from collaboration and licensing agreements and governmental funding [33] - Operating expenses were €72.5 million, a 5% increase compared to 2020, with R&D expenses at €47 million, decreasing by 5% [34] Business Line Data and Key Metrics Changes - The lead proprietary product candidate, lacutamab, is in development for T-cell lymphoma, with significant progress in clinical trials [6][9] - The company initiated two trials in the larger indication of peripheral T-cell lymphoma [10] - Monalizumab, an anti-NKG2A, is involved in two ongoing Phase 3 trials in lung cancer and head and neck cancer [20][24] Market Data and Key Metrics Changes - The market for Sézary syndrome is niche, with about 100 to 200 new cases annually, while mycosis fungoides represents a larger opportunity with approximately 3,000 to 4,000 new patients each year [78] - The cutaneous T-cell lymphoma market is not large compared to peripheral T-cell lymphoma, which has nearly 20,000 new patients annually [78] Company Strategy and Development Direction - The company focuses on three key priorities: advancing lacutamab, leveraging antibody engineering capabilities, and building sustainable partnerships [6] - The ANKET platform is being developed to create a new class of tri- and tetra-specific molecules for cancer treatment [25][27] - The company aims to position itself for long-term value creation through strategic investments and partnerships [43] Management Comments on Operating Environment and Future Outlook - Management expects to report preliminary data from the TELLOMAK study for lacutamab in the second half of 2022 [40] - The company is optimistic about the development of the ANKET technology platform and its potential in the clinic [42] - There is a focus on advancing the adenosine pathway agents, with data from anti-CD39 expected in 2023 [41] Other Important Information - The company has a strong cash position, estimated to fund operations through at least 2023 [37] - The interim analysis for the INTERLINK study is expected in the second half of 2022 [69] Q&A Session Summary Question: Can you confirm the purpose of the new all-comers cohort in mycosis fungoides? - The all-comers cohort will evaluate an FFPE companion diagnostic approach and is integrated into the TELLOMAK study without delaying development [50] Question: What is the regulatory strategy for Sézary syndrome? - The initial strategy is a fast-to-market approach, with potential for a combined registration for both Sézary syndrome and mycosis fungoides [71] Question: What are the challenges and opportunities in developing tetra ANKET products? - The main opportunity lies in the safety of NK-cell engagers compared to T-cell engagers, while challenges include ensuring the safety profile translates into clinical benefits [78]

Innate Pharma S.A. (NASDAQ:IPHA) Q3 2021 Results Earnings Conference Call November 16, 2021 8:00 AM ET Company Participants Mondher Mahjoubi - Chairman of Executive Board and Chief Executive Officer Joyson Karakunnel - Executive Vice President and Chief Medical Officer Yannis Morel - Executive Vice President, Product Portfolio Strategy and Business Development Conference Call Participants Yigal Nochomovitz - Citigroup Daina Graybosch - SVB Leerink Keyur Parekh - Goldman Sachs Olga Smolentseva - Bryan Garnie ...

Third Quarter 2021 Business Update November 16, 2021 PARIS: IPH.PA NASDAQ: IPHA © 2021 Innate Pharma. All rights reserved. Disclaimer on Forward-Looking Information and Risk Factors This document has been prepared by Innate Pharma S.A. (the "Company") solely for the purposes of a presentation to investors concerning the Company. This document is not to be reproduced by any person, nor to be distributed. This document contains forward-looking statements. The use of certain words, including "believe," "potent ...

Innate Pharma S.A. (OTCPK:IPHYF) Q2 2021 Earnings Conference Call September 15, 2021 8:00 AM ET Company Participants Mondher Mahjoubi - Chairman of Executive Board & CEO Joyson Karakunnel - EVP & Chief Medical Officer Frédéric Lombard - SVP, Chief Financial Officer Henry Wheeler - IR Conference Call Participants Daina Graybosch - SVB Leerink Yigal Nochomovitz - Citigroup Graig Suvannavejh - Goldman Sachs Operator Good day, and thank you for standing by, and welcome to the Innate Pharma Half Year Results Con ...

Half Year 2021 Business Update September 15, 2021 PARIS: IPH.PA NASDAQ: IPHA © 2021 Innate Pharma. All rights reserved. Disclaimer on Forward-Looking Information and Risk Factors This document has been prepared by Innate Pharma S.A. (the "Company") solely for the purposes of a presentation to investors concerning the Company. This document is not to be reproduced by any person, nor to be distributed. This document contains forward-looking statements. The use of certain words, including "believe," "potential ...